MONTRÉAL, June 7, 2023 – Developing new generations of immunotherapies to treat currently incurable pediatric leukemia is the mission of…
We are thrilled to welcome a new director to the board of directors of Immune Biosolutions Inc: Mr. Nicholas Franco….
SHERBROOKE, QC, Jan. 10, 2022 /CNW Telbec/ Immune Biosolutions Inc., a clinical-stage company, is pleased to announce that its leading biological drug…
Immune Biosolutions is pleased to announce the start of Phase I clinical trial for its immunotherapy (IBIO123) treatment, whose antibodies have the potential to neutralize and eliminate COVID-19 and its variants. The treatment has the ability of being administered by inhalation and acts in a highly targeted manner through the lungs to fight the infection at its source.
SHERBROOKE, Québec (March 16, 2021)—Immune Biosolutions, an innovative biotechnology company, receives $13.44M from the Government of Canada’s Strategic Innovation Fund…
Sherbrooke, April 20 2020 – Immune Biosolutions, Diex Research, Keyrus Life Science and the Faculty of Medicine and Health Sciences of the…
Sherbrooke, Qc, CA, January 15th, 2020 – Immune Biosolutions, an early-stage biopharmaceutical company focusing on the discovery, engineering and development…
Immune Biosolutions has been selected to present its Edible Antibodies technology in the G20 Young Entrepreneurs Alliance Event in Fukuoka,…
Chief executive officer, Frédéric Leduc, will be representing Immune Biosolutions this week at the 24th edition of BIO-Europe in Copenhagen…
Immune Biosolutions Enters into a Research Collaboration and License Agreement with Johnson & Johnson Innovation to Identify and Develop Therapeutic…
After winning a pitch competition earlier this year, Immune Biosolutions’ founders are participating this week in the Futurpreneur’s Growth Accelerator…
CQDM to support a $1.1 million research and development project for Immune Biosolutions’ next-generation of anti-cancer treatment BOSTON, JUNE 6,…
